According to a report by Indonesian media VIVA on August 31st, the Indonesian Parliament (DPR) recently passed the "Health Law No. 17 of 2023". This law is seen as providing legal certainty for the e-cigarette industry, as it categorizes e-cigarettes as addictive substances.
The Chairman of the Indonesian Electronic Nicotine Industry Alliance (APPNINDO), Teguh Basuki A Wibowo, has expressed that including e-cigarettes as a part of the legal framework for solid and liquid tobacco products not only legalizes participants in the industry but also helps Indonesian smokers find alternatives.
Tagu explained that this law also provides the public with greater freedom of choice to determine alternative products under legal protection.
We look forward to the government formulating e-cigarette industry-related policies based on scientific evidence in the future.
He further stated that this law puts Indonesia on an equal footing with other countries that have similar legislative frameworks regarding e-cigarettes, such as the Philippines and the United Kingdom. These countries have regulations in place for the distribution and quality of e-cigarettes, restricting their consumption to adults only.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
